| Tebas, Pablo |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery |
|
|
| Not yet recruiting | 2 | 99 | US | GLS-1200, Placebo, Sterile Saline | GeneOne Life Science, Inc. | Sinusitis Chronic | 12/23 | 09/24 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 |
|
|
| Active, not recruiting | 1 | 15 | US | Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies | Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, HIV/AIDS, HIV-1 Infection | 12/21 | 10/22 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Active, not recruiting | 1 | 61 | US | dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals | Healthy Volunteers | 09/25 | 09/25 | | |
| Active, not recruiting | 1 | 12 | US | CD4 CAR+CCR5 ZFN T-cells | University of Pennsylvania | Hiv | 12/26 | 12/27 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| Deville, Jaime |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 |
|
|
| Completed | 3 | 101 | US, RoW | Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets | ViiV Healthcare | HIV Infections | 12/24 | 12/24 | | |
NCT04462848: Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions |
|
|
| Not yet recruiting | 1 | 30 | US | anti-SARS-CoV-2 human convalescent plasma | University of California, Los Angeles | Corona Virus Infection | 09/24 | 12/24 | | |
| Recruiting | 1 | 67 | US | Vabomere, Combination meropenem and vaborbactam, carbapenem and beta-lactamase inhibitor | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Department of Health and Human Services | Bacterial Infections | 12/24 | 06/25 | | |
NCT01527591: Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT) |
|
|
| Active, not recruiting | N/A | 17 | US | Pneumococcal Conjugate Vaccine 13 (PCV13), Prevnar13® | University of California, Los Angeles | Infection in Solid Organ Transplant Recipients | 12/23 | 06/24 | | |
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) |
|
|
| Recruiting | N/A | 5000 | Canada, US | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome | 09/26 | 09/27 | | |
| Active, not recruiting | N/A | 334 | US | | Harvard School of Public Health (HSPH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Allergy and Infectious Diseases (NIAID), NIH Office of AIDS Research (OAR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Heart, Lung, and Blood Institute (NHLBI) | HIV/AIDS | 07/25 | 07/25 | | |
NCT05154513: Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV |
|
|
| Recruiting | N/A | 250 | US, RoW | Cohort 1 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | HIV Infection | 11/27 | 11/27 | | |
| Landovitz, Raphael J |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
HPTN 083, NCT02720094: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
|
|
| Active, not recruiting | 2/3 | 4570 | US, RoW | Cabotegravir Oral Tablet, Oral cabotegravir, TDF/FTC tablets, Truvada, Placebo for TDF/FTC tablets, Placebo for Truvada, Placebo for cabotegravir oral tablet, Placebo for oral cabotegravir, CAB LA, Long acting cabotegravir, Injectable cabotegravir, Placebo for CAB LA, Placebo for long acting cabotegravir | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Gilead Sciences | HIV Infections | 05/20 | 04/25 | | |
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M) |
|
|
| Not yet recruiting | 2 | 200 | US | CAB LA, New formulation of CAB LA | ViiV Healthcare | HIV Infections | 08/26 | 12/28 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
| Taiwo, Babafemi |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 128 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
iCARE, NCT04950153: Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase |
|
|
| Active, not recruiting | N/A | 558 | RoW | Peer navigation, SMS Text messaging, Social Media Engagement, Testing Peer Navigation | Northwestern University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Adolescent HIV Infection | 08/24 | 12/24 | | |
NCT06190613: Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria |
|
|
| Recruiting | N/A | 100 | RoW | Combination Peer navigation and mHealth intervention | Northwestern University, National Institute of Mental Health (NIMH) | HIV | 08/26 | 08/26 | | |
| Burke, Leah |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
| Recruiting | N/A | 300 | US | Acceptance and Commitment Therapy (ACT), Body weight circuit training, Empathetic social support, Control - list of resources | University of California, San Diego, Christie's Place, By His Stripes Wellness Center, Sister Love, APLA Health | HIV Infections, Substance Use, Trauma, Medication Adherence | 12/27 | 05/28 | | |
| Akha, Arezou S |
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions |
|
|
| Active, not recruiting | 3 | 91 | US | imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas | Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection | 12/23 | 04/25 | | |
NCT02437851: Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection |
|
|
| Active, not recruiting | 2 | 16 | US | Therapeutic Conventional Surgery | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, AIDS and Cancer Specimen Resource, University of Arkansas | Anal Squamous Cell Carcinoma, HIV Infection, Stage 0 Anal Canal Cancer, Stage I Anal Canal Cancer | 03/26 | 03/26 | | |
NCT03603808: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions |
|
|
| Active, not recruiting | 2 | 35 | US | Electroporation, electroporation therapy, EPT, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, VGX-3100, Laboratory Biomarker Analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Inovio Pharmaceuticals | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | 01/26 | 01/27 | | |
NCT06055868: People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity |
|
|
| Not yet recruiting | N/A | 144 | US | Group Meeting (Focus Group), Questionnaires | University of California, San Francisco, National Institute of Dental and Craniofacial Research (NIDCR) | HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | 11/29 | 11/29 | | |
| Khodabakhshian, Aleen |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT06560684: CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR |
|
|
| Recruiting | 2 | 150 | US | Oral F/TDF Pills, TFV rectal douche | National Institute of Allergy and Infectious Diseases (NIAID) | Tenofovir | 01/26 | 01/26 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) |
|
|
| Active, not recruiting | 2 | 90 | US | CMV-MVA Triplex, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Cytomegalovirus Infections, HIV Infections, Vaccine | 11/24 | 10/25 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Hendrickx, Steven |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) |
|
|
| Active, not recruiting | 2 | 90 | US | CMV-MVA Triplex, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Cytomegalovirus Infections, HIV Infections, Vaccine | 11/24 | 10/25 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, GS-2872, 10-1074-LS, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/26 | 04/26 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 600 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 06/25 | 12/25 | | |
| Leader, CRS |
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants |
|
|
| Completed | 1 | 38 | RoW | CH505TF gp120, GLA-SE adjuvant, Placebo | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 07/24 | 07/24 | | |
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study |
|
|
| Active, not recruiting | N/A | 13 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 02/25 | 02/25 | | |
| Pearson, Greer |
NCT06560684: CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR |
|
|
| Recruiting | 2 | 150 | US | Oral F/TDF Pills, TFV rectal douche | National Institute of Allergy and Infectious Diseases (NIAID) | Tenofovir | 01/26 | 01/26 | | |
